Great Lakes Retirement Inc. Has $7.65 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Great Lakes Retirement Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 13,122 shares of the company’s stock after buying an additional 999 shares during the quarter. Eli Lilly and Company comprises about 1.3% of Great Lakes Retirement Inc.’s portfolio, making the stock its 22nd largest holding. Great Lakes Retirement Inc.’s holdings in Eli Lilly and Company were worth $7,649,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $27,000. Retirement Group LLC lifted its position in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $33,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $35,000. Finally, Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 14,388 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares in the company, valued at $62,873,217,098.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 195,055 shares of company stock worth $125,254,657 over the last ninety days. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LLY. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Barclays boosted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Truist Financial restated a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Stock Performance

LLY traded up $3.79 during trading on Wednesday, hitting $778.69. 2,297,294 shares of the company traded hands, compared to its average volume of 3,236,753. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock’s fifty day moving average is $727.96 and its 200 day moving average is $636.01. The firm has a market cap of $739.88 billion, a P/E ratio of 133.96, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34. Eli Lilly and Company has a one year low of $334.58 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the business earned $2.09 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts predict that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.